Market closedNon-fractional
G1 Therapeutics/GTHX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About G1 Therapeutics
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Ticker
GTHX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Research Triangle Park, United States
Employees
100
Website
www.g1therapeutics.com
G1 Therapeutics Metrics
BasicAdvanced
$207M
Market cap
-
P/E ratio
-$0.59
EPS
1.71
Beta
-
Dividend rate
Price and volume
Market cap
$207M
Beta
1.71
Financial strength
Current ratio
2.94
Quick ratio
2.357
Long term debt to equity
148.322
Total debt to equity
169.757
Interest coverage (TTM)
-2.56%
Management effectiveness
Return on assets (TTM)
-10.81%
Return on equity (TTM)
-84.13%
Valuation
Price to revenue (TTM)
2.438
Price to book
7.48
Price to tangible book (TTM)
7.48
Price to free cash flow (TTM)
-11.267
Growth
Revenue change (TTM)
46.55%
Earnings per share change (TTM)
-78.42%
3-year revenue growth (CAGR)
12.20%
3-year earnings per share growth (CAGR)
-37.70%
What the Analysts think about G1 Therapeutics
Analyst Ratings
Majority rating from 6 analysts.
G1 Therapeutics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$14M
-2.70%
Net income
-$10M
-5.56%
Profit margin
-70.83%
-2.93%
G1 Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.14
-$0.35
-$0.21
-$0.20
-
Expected
-$0.22
-$0.33
-$0.28
-$0.21
-$0.17
Surprise
-164.00%
6.38%
-23.69%
-2.72%
-
G1 Therapeutics News
AllArticlesVideos
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
GlobeNewsWire·1 day ago
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
GlobeNewsWire·4 weeks ago
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for G1 Therapeutics stock?
G1 Therapeutics (GTHX) has a market cap of $207M as of July 26, 2024.
What is the P/E ratio for G1 Therapeutics stock?
The price to earnings (P/E) ratio for G1 Therapeutics (GTHX) stock is 0 as of July 26, 2024.
Does G1 Therapeutics stock pay dividends?
No, G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next G1 Therapeutics dividend payment date?
G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders.
What is the beta indicator for G1 Therapeutics?
G1 Therapeutics (GTHX) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell G1 Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.